Inclusion Criteria:

• Adult patients aged 18 to 70 who have been clinically diagnosed with CIPN for greater than six months after stopping chemotherapy.

• Average pain intensity ≥ 5 on 11-point numeric rating scale (NRS) in the lower extremities at enrollment.

• Failed conventional medication management with at least two neuropathic pain medications.

• Have electrophysiological evidence of length-dependent peripheral neuropathy.

• Underwent a 10-kHz spinal cord stimulator implant for a primary indication of CIPN.

• Have stable neurological status.

• Be on a stable analgesic regimen.

• Be an appropriate candidate for surgical procedures required in this study.

• Be able to read and understand English-written questionnaires and sign an informed consent form in English.

• Be willing and capable of giving informed consent.

• Be willing and able to complete study-related requirements, procedures, and visits.

Exclusion Criteria:

• Patient refusal to be included in study.

• Presence of lower limb mononeuropathy.

• History of lower limb amputation or ulceration.

• Presence of another painful condition that is unrelated to CIPN and that is not intended to be treated in this study.

• BMI ≥ 40.

• OME > 120 mg.

• Progressive neurological disease (multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, Complex Regional Pain Syndrome, acute herniating disc, severe spinal stenosis).

• Certain comorbidities: coagulation/bleeding disorders, diminished capacity from cardiac/pulmonary disease.

• Obtaining another interventional procedure unrelated to SCS to treat limb pain.

• Have ongoing metastatic malignant neoplasm or untreated local malignant neoplasm. Included patients must be deemed as in remission per discretion of treating oncologist.

• Have a life expectancy of less than one year.

• Have untreated addiction or dependency to medications, alcohol, or illicit drugs.

• Have active, disruptive, and/or unstable psychological or psychiatric disorder.

Eligibility last updated 2/2/22. Questions regarding updates should be directed to the study team contact.